Grifols, S.A. (GRFS) News

Grifols, S.A. (GRFS): $18.70

1.05 (+5.95%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter GRFS News Items

GRFS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GRFS News Highlights

  • 500 - Internal server error
  • Over the past 16 days, the trend for GRFS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about GRFS are PD, VIVO and BIO.

Latest GRFS News From Around the Web

Below are the latest news stories about Grifols SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

Kepler Capital Stick to Their Hold Rating for Grifols SA By Investing.com

Kepler Capital Stick to Their Hold Rating for Grifols SA

Investing.com | June 4, 2021

Grifols to provide Korean Red Cross with Procleix Panther for blood screening, extending donor testing leadership in Asia

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and innovative diagnostic solutions, today announced it will provide the Korean Red Cross (KRC) with its industry-leading Procleix Panther System running nucleic acid testing (NAT) technology to help ensure the safety of South Korea's blood supply.

Yahoo | June 3, 2021

Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new formulation of its hepatitis B immune globulin [human] for hepatitis B postexposure prophylaxis.

Yahoo | June 1, 2021

GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies

SOUTH SAN FRANCISCO, May 25, 2021 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, and a subsidiary of Grifols, announced today publication of research, titled, “Single cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment,” in the peer-reviewed journal BMC Biology. The preclinical data describes potential new avenues to overcome resistance to anti-PD-L1 therapies. “A major goal in oncology is to find strategies that enhance the infiltration of immune T cells in the tumor to improve efficacy of therapies, while reducing resistance and toxic effects,” said Erica Stone, Ph.D., vice president of Oncology at GigaGen and auth...

Yahoo | May 25, 2021

Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and well-being of people, today announced it's collaborating with the medical foundation Ace Alzheimer Center Barcelona to open the first AMBAR® Center, where AMBAR® procedure for Alzheimer's disease will be applied to obtain data from clinical practice.

Yahoo | May 19, 2021

Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021

Grifols, S.A. ("Grifols") (MCE: GRF), (MCE: GRF.P) and (NASDAQ: GRFS) announced that it has filed its 2020 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April 9, 2021. Grifols' Annual Report on Form 20-F includes its audited financial statements for its fiscal year ended December 31, 2020.

Yahoo | April 9, 2021

Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's health and well-being, today announced that the Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trial, also known as INSIGHT-013, sponsored and supported by the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), did not meet its primary endpoints with statistically significant results.

Yahoo | April 2, 2021

Blood Plasma Derivatives Market Size to Grow at a Remarkable Pace in the Coming Years : Grifols, S.A., SK Plasma Co., Ltd., Fusion Health Care Pvt. Ltd., Biotest AG

The insight Partners Research has recently added a concise research on the Global Blood Plasma Derivatives Market – Industry Trends and Forecast to 2027. A reliable Global Blood Plasma Derivatives Market report contains market data that can be relatively essential

OpenPR | March 22, 2021

Grifols installs first-ever DG Reader Net analyzer in North America

BARCELONA, Spain , March 22, 2021 /PRNewswire/ -- Grifols ((MCE: GRF, MCE: GRF.P, NASDAQ: GRFS ), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today announced its first-ever installation in North America of the DG Reader Net semi-automated analyzer, used to facilitate pre-transfusion blood type compatibility testing. This platform, the newest addition to the company's scalable solutions for blood banks, is now running at ThedaCare Medical Center-Wild Rose in Wisconsin . Many small, specialized laboratories like ThedaCare Medical Center-Wild Rose work hard to offer high quality service in pre-transfusion testing with limited semi-automated solutions available to them, resulting in manual testing that coul...

Benzinga | March 22, 2021

Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people worldwide, today announced the closing of its agreement with GigaGen Inc. to acquire its remaining 56% share capital for USD 80 million.

Yahoo | March 9, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6358 seconds.